8-K: ZyVersa Therapeutics Delisted from Nasdaq

ZyVersa Therapeutics, Inc. announced its common stock will be delisted from the Nasdaq Stock Market due to failure to meet minimum bid price requirements.

Summary

• Nasdaq notified ZyVersa Therapeutics, Inc. (the Company) on September 14, 2025, of its plan to delist the Company's common stock.
• Nasdaq will file a Form 25 with the SEC on or about September 18, 2025, to complete the delisting.
• The delisting will become effective ten days after the Form 25 is filed.
• The Company's common stock was suspended from trading on The Nasdaq Capital Market on July 17, 2025.
• Trading has continued on the OTCQB Venture Market under the symbol ZVSA since July 28, 2025, and will continue without disruption.
• The delisting stems from the Company's failure to regain compliance with Nasdaq Listing Rule 5550(a)(2) regarding minimum bid price requirements, as previously reported on July 16, 2025.

Sentiment

Score: 3

Explanation: The delisting from Nasdaq is a significant negative event, reflecting a failure to meet basic listing requirements. While trading continues on OTCQB, this typically implies reduced liquidity and investor confidence. The lack of financial metrics or positive operational updates further contributes to a low sentiment score.

Positives

• Common stock will continue trading on the OTCQB Venture Market without disruption.

Negatives

• Delisting from the Nasdaq Stock Market.
• Failure to regain compliance with Nasdaq's minimum bid price requirements (Listing Rule 5550(a)(2)).
• Suspension of trading on The Nasdaq Capital Market occurred on July 17, 2025.

Risks

• Actual results and timing of events could differ materially from forward-looking statements due to various important factors.
• Factors discussed under "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, could cause actual results to differ materially from those indicated by the forward-looking statements.

Future Outlook

The Company's common stock will continue trading on the OTCQB Venture Market without disruption following the Nasdaq delisting. The timing of the delisting is anticipated to be ten days after Nasdaq files Form 25 with the SEC on or about September 18, 2025.

Management Comments

• The Company assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

Industry Context

Delisting from a major exchange like Nasdaq to the OTCQB Venture Market is a significant event for a publicly traded company, often indicating challenges in meeting listing standards, particularly financial ones like minimum bid price. For biotechnology companies, maintaining Nasdaq listing is crucial for visibility, liquidity, and attracting institutional investment, as OTC markets typically have lower liquidity and less stringent reporting requirements, which can deter some investors. This move could impact the company's ability to raise capital and its overall market perception compared to peers maintaining major exchange listings.

Stakeholder Impact

• Shareholders will experience reduced liquidity and potentially lower share price due to the move from Nasdaq to OTCQB. Institutional investors may be restricted from holding shares on OTC markets.
• The Company may face challenges in raising capital and attracting new investors due to decreased visibility and perceived risk associated with OTC trading.

Next Steps

• Nasdaq will file a Form 25 with the SEC on or about September 18, 2025.
• The delisting will become effective ten days after the Form 25 is filed.

Key Dates

Recommendation

The delisting from Nasdaq due to failure to meet minimum bid price requirements is a severe negative indicator for the company's financial health and market standing. While trading continues on the OTCQB, this typically leads to significantly reduced liquidity, lower investor confidence, and a higher cost of capital. For a seasoned investor, this event signals fundamental issues that make the stock a high-risk, low-return proposition, warranting a sell recommendation to mitigate further potential losses.

Keywords

ZyVersa Therapeutics, ZVSA, Nasdaq delisting, OTCQB, minimum bid price, SEC filing, 8-K, biotechnology, pharmaceuticals